Status:
TERMINATED
Treatment of Nosocomial COVID-19
Lead Sponsor:
University of Calgary
Collaborating Sponsors:
Sunnybrook Research Institute
Conditions:
Covid19
Nosocomial Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. Nosocomial acquisition of SARS-CoV-2 is a frequent concern across hospital ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay, in any specimen prior to randomization.
- Admitted to a participating centre
- Is nosocomially acquired infection, as defined by ALL of:
- COVID19 diagnosis being made on admission day three or later;
- Admitted for a reason other than COVID19;
- Within 5 days of COVID19 diagnosis based on test collection date or initial development of symptoms, which ever was earliest.
Exclusion
- Plan for palliation within 24 hours
- Known allergy to study medication or its components (non-medicinal ingredients)
- Ordinal scale 6 or above
- Admitted to facility for non-medical reasons including primary psychiatric diagnosis or labour and delivery.
- Pregnancy or breast feeding
- Weight less than 40kg
Key Trial Info
Start Date :
February 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04748588
Start Date
February 12 2021
End Date
January 31 2022
Last Update
April 19 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N1N4
2
University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
3
Hôpital Montfort
Ottawa, Ontario, Canada, K1K0T2
4
Michael Garron Hospital
Toronto, Ontario, Canada, M4C3E7